131 related articles for article (PubMed ID: 1449132)
1. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori.
Chiba N; Rao BV; Rademaker JW; Hunt RH
Am J Gastroenterol; 1992 Dec; 87(12):1716-27. PubMed ID: 1449132
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of triple therapy to eradicate H. pylori in patients after failed therapy with omeprazole/amoxicillin].
Zala G; Schwery S; Giezendanner S; Flury R; Wüst J; Meyenberger C; Wirth HP
Schweiz Med Wochenschr; 1996 Feb; 126(5):153-8. PubMed ID: 8685685
[TBL] [Abstract][Full Text] [Related]
3. [Eradication of Helicobacter pylori infection in Europe: a meta-analysis based on congress abstracts, 1997-2002].
Buzás GM; Józan J
Orv Hetil; 2004 Oct; 145(40):2035-41. PubMed ID: 15559530
[TBL] [Abstract][Full Text] [Related]
4. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
[TBL] [Abstract][Full Text] [Related]
5. A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Lerang F; Moum B; Ragnhildstveit E; Haug JB; Hauge T; Tolås P; Aubert E; Henriksen M; Efskind PS; Nicolaysen K; Søberg T; Odegaard A; Berge T
Am J Gastroenterol; 1997 Apr; 92(4):653-8. PubMed ID: 9128317
[TBL] [Abstract][Full Text] [Related]
6. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Bago J; Halle ZB; Strinić D; Kućisec N; Jandrić D; Bevanda M; Tomić M; Bilić A
Wien Klin Wochenschr; 2002 Jun; 114(12):448-53. PubMed ID: 12422579
[TBL] [Abstract][Full Text] [Related]
7. Pylera for the eradication of Helicobacter pylori infection.
Saleem A; Qasim A; O'Connor HJ; O'Morain CA
Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
[TBL] [Abstract][Full Text] [Related]
8. Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
de Boer WA; Haeck PW; Otten MH; Mulder CJ
Am J Gastroenterol; 1998 Jul; 93(7):1101-7. PubMed ID: 9672338
[TBL] [Abstract][Full Text] [Related]
9. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
[TBL] [Abstract][Full Text] [Related]
10. Reduced symptoms and need for antisecretory therapy in veterans 3 years after Helicobacter pylori eradication with ranitidine bismuth citrate/amoxicillin/clarithromycin.
Sontag SJ; O'Connell S; Schnell T; Chejfec G; Seidel J; Sonnenberg A
Am J Gastroenterol; 2001 May; 96(5):1390-5. PubMed ID: 11374672
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Park KN; Hahm JS; Kim HJ
Eur J Gastroenterol Hepatol; 1994 Dec; 6 Suppl 1():S103-7. PubMed ID: 7735924
[TBL] [Abstract][Full Text] [Related]
12. Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection.
de Boer WA
Eur J Gastroenterol Hepatol; 1999 Jul; 11(7):697-700. PubMed ID: 10445785
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Vakil N; Fennerty MB
Am J Gastroenterol; 1996 Feb; 91(2):239-45. PubMed ID: 8607487
[TBL] [Abstract][Full Text] [Related]
14. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
Gisbert JP; Fuentes J; Carpio D; Tito L; Guardiola J; Tomas A; Olivares D; Calvet X
Aliment Pharmacol Ther; 2005 May; 21(10):1249-53. PubMed ID: 15882246
[TBL] [Abstract][Full Text] [Related]
15. Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
Thijs JC; van Zwet AA; Moolenaar W; Wolfhagen MJ; ten Bokkel Huinink J
Am J Gastroenterol; 1996 Jan; 91(1):93-7. PubMed ID: 8561152
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori.
Taylor JL; Zagari M; Murphy K; Freston JW
Arch Intern Med; 1997 Jan; 157(1):87-97. PubMed ID: 8996045
[TBL] [Abstract][Full Text] [Related]
17. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
[TBL] [Abstract][Full Text] [Related]
18. Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Uygun A; Ozel AM; Yildiz O; Aslan M; Yesilova Z; Erdil A; Bagci S; Gunhan O
J Gastroenterol Hepatol; 2008 Jan; 23(1):42-5. PubMed ID: 17559359
[TBL] [Abstract][Full Text] [Related]
19. The efficacy of two-week therapy with ranitidine bismuth citrate, amoxicillin and clarithromycin on Helicobacter pylori eradication in clarithromycinresistant and- sensitive cases.
Aydin A; Onder GF; Akarca US; Tekin F; Tunçyürek M; Musoğlu A
Turk J Gastroenterol; 2005 Dec; 16(4):203-6. PubMed ID: 16547848
[TBL] [Abstract][Full Text] [Related]
20. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
